'Another complicating factor was that Oncosil’s application marked the first time anadvisory body called the Clinical Oversight Committee was involved in the approvalprocess for an active implantable medical device.' http://www.biotechdaily.com.au/media/Dr%20Boreham/OSL%20May%2024%202019.pdf Interesting how Oncosil made absolutely no reference to the Committee, or the fact that it was the first time being used for such an approval, in any previous investor briefings or other comms. I still believe (although I'm no lawyer) the laguage of "extremely confident" and "imminent" and the non-mention of the oversight committee is potentially grounds for class action on the grounds that full and continuous disclosure was not maintained...
OSL Price at posting:
6.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)